康弘药业
(002773)
| 流通市值：137.89亿 | | | 总市值：185.09亿 |
| 流通股本：6.85亿 | | | 总股本：9.19亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,092,784,087.91 | 3,957,459,641.68 | 2,998,812,667.01 | 1,920,404,752.87 |
| 营业收入 | 1,092,784,087.91 | 3,957,459,641.68 | 2,998,812,667.01 | 1,920,404,752.87 |
| 二、营业总成本 | 658,811,628.42 | 2,807,068,148.65 | 2,065,539,720.1 | 1,335,553,729.99 |
| 营业成本 | 114,856,552.26 | 438,408,929.52 | 326,425,918.21 | 214,892,618.75 |
| 税金及附加 | 13,200,291.65 | 56,082,041.98 | 38,167,479.08 | 28,479,146.04 |
| 销售费用 | 387,756,159.6 | 1,470,869,100.56 | 1,175,711,235.88 | 741,341,793.96 |
| 管理费用 | 95,452,003.64 | 472,383,257.5 | 306,304,894.28 | 206,478,918.5 |
| 研发费用 | 63,845,609.61 | 421,678,043.03 | 258,348,158.9 | 170,098,530.31 |
| 财务费用 | -16,298,988.34 | -52,353,223.94 | -39,417,966.25 | -25,737,277.57 |
| 其中:利息收入 | 15,419,989.88 | 52,503,037.47 | 40,104,975.13 | 25,600,096.79 |
| 加:公允价值变动收益 | 268,800 | -832,800 | -218,400 | - |
| 加:投资收益 | -53,158.67 | 45,031,602.19 | 21,842,671.01 | 17,942,130.38 |
| 资产处置收益 | - | 9,026.5 | -51,392.92 | - |
| 资产减值损失(新) | - | -230,528.34 | 126,527.22 | 983,616.72 |
| 信用减值损失(新) | -356,208.51 | -1,317,213.7 | -1,041,081.07 | -1,842,015.64 |
| 其他收益 | 12,706,363.11 | 68,016,071.72 | 41,439,119.25 | 28,618,262.58 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 446,538,255.42 | 1,261,067,651.4 | 995,370,390.4 | 630,553,016.92 |
| 加:营业外收入 | 249,109.89 | 1,372,815.49 | 5,145,084.71 | 4,913,023.77 |
| 减:营业外支出 | 805,676.37 | 28,523,493.61 | 18,314,457.21 | 14,390,057.69 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 445,981,688.94 | 1,233,916,973.28 | 982,201,017.9 | 621,075,983 |
| 减:所得税费用 | 74,506,590.89 | 202,793,059.07 | 165,993,916.71 | 101,368,906.76 |
| 六、净利润 | 371,475,098.05 | 1,031,123,914.21 | 816,207,101.19 | 519,707,076.24 |
| 持续经营净利润 | 371,475,098.05 | 1,031,123,914.21 | 816,207,101.19 | 519,707,076.24 |
| 归属于母公司股东的净利润 | 373,521,473.06 | 1,044,765,761.76 | 825,361,369.22 | 525,339,192.02 |
| 少数股东损益 | -2,046,375.01 | -13,641,847.55 | -9,154,268.03 | -5,632,115.78 |
| (一)基本每股收益 | 0.41 | 1.14 | 0.9 | 0.57 |
| (二)稀释每股收益 | 0.41 | 1.14 | 0.9 | 0.57 |
| 八、其他综合收益 | -586,682.08 | -291,301.28 | -205,102.74 | -47,402.9 |
| 归属于母公司股东的其他综合收益 | -586,682.08 | -291,301.28 | -205,102.74 | -47,402.9 |
| 九、综合收益总额 | 370,888,415.97 | 1,030,832,612.93 | 816,001,998.45 | 519,659,673.34 |
| 归属于母公司股东的综合收益总额 | 372,934,790.98 | 1,044,474,460.48 | 825,156,266.48 | 525,291,789.12 |
| 归属于少数股东的综合收益总额 | -2,046,375.01 | -13,641,847.55 | -9,154,268.03 | -5,632,115.78 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-27 | 2023-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |